19885-10-0
Chemical Structure
Alisol A
- CAS No.: 19885-10-0
- Formula:C30H50O5
- Molecular Weight:490.72
IUPAC Name: (5R,8S,9S,10S,11S,14R)-11-hydroxy-4,4,8,10,14-pentamethyl-17-((2R,4S,5R)-4,5,6-trihydroxy-6-methylheptan-2-yl)-1,2,4,5,6,7,8,9,10,11,12,14,15,16-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one
InChIKey: HNOSJVWYGXOFRP-UNPOXIGHSA-N
SMILES: C[C@]([C@@]1(C2=C([C@H](C)C[C@H](O)[C@@H](O)C(C)(O)C)CC1)C)(CC[C@@]3([H])C4(C)C)[C@]([C@H](C2)O)([H])[C@]3(CCC4=O)C
Biological Activity: Alisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Alisol A | 99.59% | Alisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Alisol A (Standard) | ≥98% | Alisol A (Standard) is the analytical standard of Alisol A (HY-N0853). This product is intended for research and analytical applications. Alisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Matsuda H, et al. Studies on Alismatis Rhizoma. II. Anti-complementary activities of methanol extract and terpene components from Alismatis Rhizoma (dried rhizome of Alisma orientale). Biol Pharm Bull. 1998 Dec;21(12):1317-21. [Content Brief]
- [2]. Zhang Q, et al. Anti-HBV agents. Part 1: Synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4647-50. [Content Brief]
- [3]. Lou C, et al. Alisol A Suppresses Proliferation, Migration, and Invasion in Human Breast Cancer MDA-MB-231 Cells. Molecules. 2019 Oct 10;24(20):3651. [Content Brief]
- [4]. Ho C, et al. Alisol A attenuates high-fat-diet-induced obesity and metabolic disorders via the AMPK/ACC/SREBP-1c pathway. J Cell Mol Med. 2019 Aug;23(8):5108-5118. [Content Brief]
- [5]. Ma Y, et al. Alisol A inhibits and stabilizes atherosclerotic plaques by protecting vascular endothelial cells. Front Pharmacol. 2024 Oct 25;15:1493948. [Content Brief]
- [6]. Han W, et al. Alisol A attenuates malignant phenotypes of colorectal cancer cells by inactivating PI3K/Akt signaling. Oncol Lett. 2022 Jun 7;24(2):249. [Content Brief]
- [7]. Wang K, et al. Alisol A Alleviates Arterial Plaque by Activating AMPK/SIRT1 Signaling Pathway in apoE-Deficient Mice. Front Pharmacol. 2020 Nov 2;11:580073. [Content Brief]
Keywords
